Evidence map›Paper›PMID 41830329›Full record

ArticleNucleic acids research2026

DNA secondary structures in BCL2 and MYC elicit activation-induced cytidine deaminase binding and activity.

Mason McCrury, Ambrocio Sanchez, Rylie Mangold, Todd J Spears, Claire Doshier, Rémi Buisson, Mojnu Miah, Derin Akdeniz, Samantha Kendrick

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mason McCruryDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.ORCID 0000-0001-5127-2696
Ambrocio SanchezDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.
Rylie MangoldDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Todd J SpearsDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Claire DoshierDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Rémi BuissonDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0002-7196-8209
Mojnu MiahDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Derin AkdenizDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Samantha KendrickDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett · 2017 to 2026
$27.6M
Molecular Mechanisms of APOBEC-Induced Mutagenesis in CancerR37CA252081 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2021 to 2026
$2.5M
NF-KB regulation by the DNA damage responseR21ES036190 · NIEHS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUISSON, REMI · 2025 to 2025
$432k
Role of APOBEC3B in the Innate Immune ResponseR21AI185033 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2025 to 2026
$425k
American Cancer Society CAT-24-1374686-01-CATAmerican Cancer Society P30CA-062203Chao Family Comprehensive Cancer Center P30CA-062203GRT Hub for instrumentation 1S10OD010794-01NCI NIH HHS P30 CA062203NCI NIH HHS R37 CA252081NIAID NIH HHS R21 AI185033NIEHS NIH HHS R21 ES036190NIH HHS P20GM121293NIH HHS R37-CA252081NIH HHS R37-CA252081-S2NSF GRFP 1000350577Research Scholar Grant RSG-24-1249960-01-DMC
6 · The paper itself

Abstract

Activation-induced cytidine deaminase (AID) diversifies the immunoglobulin repertoire by targeting cytosines in specific hotspots. While AID is tightly regulated and largely confined to immunoglobulin loci, its activity at nonimmunoglobulin sites is linked to oncogenic mutagenesis. Mechanisms underlying AID targeting are not completely understood, though recent evidence indicates G4 structures are preferred AID substrates. Here, we use well-characterized structure-forming sequences from the BCL2 and MYC promoters, proposed AID off-targets in lymphoma, to investigate AID recognition of oncogene-associated secondary structures. Our work shows AID binds and deaminates G4s from both oncogenes. AID deaminates two specific cytosines in the BCL2 G4, each three nucleotides from a G-tetrad confirming previous position-dependent AID activity. Oligo-seq reveals distinct sequence contexts required for efficient deamination of these cytosines. In assessing the complementary DNA to the G4, we identify the i-Motif as a novel determinant of AID interaction. Using AID paralogs A3C, A3A, and A2, our findings highlight that DNA secondary structures differentially influence APOBEC deaminase binding and activity. Furthermore, mutation of AID residue glutamine 135 to its A3C cognate alanine disrupts both binding and deamination. This study establishes AID interacts with nonimmunoglobulin DNA structures implicating these promoter elements in AID recruitment to off-target sites in oncogenes.

Indexed as

Cytidine DeaminaseDNAProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycAICDA (Activation-Induced Cytidine Deaminase)DeaminationHumansNucleic Acid ConformationPromoter Regions, GeneticProtein BindingAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseDNAProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-myc

Identifiers

PMID41830329
PMCPMC12988328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.